Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Thematic Intelligence: Rare Disease" report has been added to ResearchAndMarkets.com's offering.
In recent years, there has been growing recognition of the importance of rare diseases as a global health priority, leading to increased research efforts, policy initiatives, and collaborative partnerships aimed at accelerating progress in this field.
Key drivers of innovation in the rare disease space include advances in genomics, molecular diagnostics, precision medicine, and therapeutic development, which hold promise for personalized approaches to diagnosis and treatment. Furthermore, the rare disease community has mobilized to advocate for greater awareness, resources, and support for individuals living with rare diseases and their families. Through grassroots activism, patient advocacy organizations, and social media campaigns, stakeholders in the rare disease space strive to amplify the voices of affected individuals, promote equitable access to care, and drive policy reforms that address the unique needs of this population.
This report consolidates the analyst's latest thinking and forecasts around how the healthcare, macroeconomic, technology, and regulatory trends will impact the rare disease space, as well as providing insights into the leading players and future disruptors across the value chain, and providing insights into key drugs and markets from the analyst's Pharma Intelligence Center. Additionally, this report is designed to provide strategic planners, competitive intelligence professionals and key stakeholders in the pharmaceutical industry a clear view of the opportunities and risks over the foreseeable future for rare disease.
Scope
- A focused chapter on the key healthcare, technology, macroeconomic, and regulatory trends impacting rare disease, and a review of the ways in which these trends will accelerate or hinder the rare disease market.
Reasons to Buy
- Understand the key trends accelerating or hindering the rare disease space.
- See market forecasts for different therapies within rare disease up to 2027.
- Understand recent and influential developments in rare disease.
- Review of leaders and disruptors across the rare disease value chain.
Key Topics Covered:
- Players
- Thematic Briefing
- Trends
- Industry Analysis
- Value Chain
- Companies
- Drug Development Scorecard
Companies Featured
- Vertex
- Roche
- Pfizer
- AstraZeneca
- Novartis
- BMS
- GSK
- IQVIA
- Lonza Group
- Catalent
- Thermo Fisher
- Sanofi,BeiGene
- Regeneron
- CSL
- Argenx
- Abzena
- Curebase
- Raremark
For more information about this report visit https://www.researchandmarkets.com/r/kzujq5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
